Pancreatic Cancer Research

ResearcherUniversity of DebrecenActive in the last 2 years

Jens Werner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7813-2482; OpenAlex author ID A5067125554. Sources: ClinicalTrials.gov.

Their work

Papers
111 (first author 6, last author 18)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
3
Collaborators
324
Papers, trials and grants by year

2011: 8 papers, 1 trial · 2012: 11 papers · 2013: 18 papers · 2014: 8 papers · 2015: 9 papers · 2016: 12 papers · 2017: 6 papers · 2018: 4 papers · 2019: 4 papers · 2020: 7 papers · 2021: 4 papers · 2022: 4 papers · 2023: 7 papers · 2024: 4 papers · 2025: 4 papers · 2026: 1 paper

Papers 50 of 111

  1. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Co-author DOI 10.1155/mi/2632235↗
  2. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Last author DOI 10.1016/j.sipas.2025.100320↗
  3. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreati… Co-author DOI 10.1097/sla.0000000000006210↗
  4. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  5. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Co-author DOI 10.1186/s12893-024-02647-1↗
  6. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  7. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  8. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  9. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  10. SPOCK2 gene expression is downregulated in pancreatic ductal adenocarcinoma cells and correlates with prognosis of patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-04845-5↗
  11. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
  12. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  13. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Last author DOI 10.1016/j.ejca.2022.12.009↗
  14. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02295-x↗
  15. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
  16. WNT enhancing signals in pancreatic cancer are transmitted by LGR6. Co-author DOI 10.18632/aging.205101↗
  17. The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. Co-author DOI 10.1002/ijc.34044↗
  18. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  19. Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac039↗
  20. Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". Last author DOI 10.1097/sla.0000000000005405↗
  21. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  22. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s12094-021-02620-x↗
  23. Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matche… Co-author DOI 10.1186/s12893-021-01083-9↗
  24. Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer. Co-author DOI 10.3390/cancers13112703↗
  25. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. Last author DOI 10.1007/s00104-020-01190-y↗
  26. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  27. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression. Co-author DOI 10.1016/j.ejso.2020.02.016↗
  28. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  29. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
  30. [Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. Co-author DOI 10.1055/a-1161-9501↗
  31. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  32. The role of interleukin-18 in pancreatitis and pancreatic cancer. Co-author DOI 10.1016/j.cytogfr.2019.11.001↗
  33. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  34. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  35. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Co-author DOI 10.3390/cancers11010039↗
  36. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s11523-018-0578-x↗
  37. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  38. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  39. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  40. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  41. Oligometastatic Disease in Pancreatic Cancer - How to Proceed? Last author DOI 10.1159/000455027↗
  42. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational resea… Co-author DOI 10.1186/s12885-017-3376-4↗
  43. Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Co-author DOI 10.1186/s40364-017-0087-6↗
  44. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. Co-author DOI 10.15252/emmm.201607354↗
  45. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). Co-author DOI 10.3390/medsci5020014↗
  46. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.10221↗
  47. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Co-author DOI 10.1002/ijc.30054↗
  48. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.30291↗
  49. [Resectability of pancreatic cancer: New criteria]. First author DOI 10.1007/s00117-016-0092-z↗
  50. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗

Trials 1

  1. Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer Principal investigator NCT01372735↗

Closest collaborators

The 25 strongest of 324 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jan Goesta D’Haese · 24 shared papers, 2015–2026 · strength 3.03
  2. Stefan Hubert Boeck · 19 shared papers, 2016–2025 · strength 2.26
  3. Steffen Ormanns · 17 shared papers, 2016–2025 · strength 2.18
  4. Bernhard Willibald Renz · 14 shared papers, 2017–2026 · strength 2.10
  5. Matthias Ilmer · 14 shared papers, 2017–2026 · strength 2.08
  6. Volker Heinemann · 15 shared papers, 2016–2023 · strength 1.86
  7. Alexandr V. Bazhin · 16 shared papers, 2013–2025 · strength 1.61
  8. Maximilian Weniger · 9 shared papers, 2018–2026 · strength 1.32
  9. Markus Wolfgang Büchler · 29 shared papers, 2011–2020 · strength 1.11
  10. Stephan Krüger · 11 shared papers, 2016–2025 · strength 1.07
  11. Michael Haas · 10 shared papers, 2016–2023 · strength 1.07
  12. Christoph Benedikt Westphalen · 10 shared papers, 2016–2023 · strength 1.04
  13. Rainer Christoph Miksch · 5 shared papers, 2019–2026 · strength 0.88
  14. Werner Hartwig · 16 shared papers, 2011–2024 · strength 0.83
  15. Hanno Nieß · 5 shared papers, 2021–2025 · strength 0.75
  16. Tobias Keck · 5 shared papers, 2019–2025 · strength 0.69
  17. Waldemar H. Uhl · 5 shared papers, 2019–2025 · strength 0.69
  18. Julia V. Mayerle · 7 shared papers, 2017–2023 · strength 0.65
  19. Iris Beirith · 4 shared papers, 2021–2025 · strength 0.63
  20. Michael Guenther · 4 shared papers, 2020–2023 · strength 0.62
  21. Michael B. Ghadimi · 4 shared papers, 2019–2025 · strength 0.59
  22. Christiane J. Bruns · 5 shared papers, 2016–2025 · strength 0.56
  23. Thilo Hackert · 14 shared papers, 2011–2016 · strength 0.54
  24. Svetlana Karakhanova · 9 shared papers, 2013–2016 · strength 0.46
  25. Jürgen Debus · 13 shared papers, 2011–2015 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.